NuGel (HY209gel)
Phase 2Topical candidate for mild-to-moderate atopic dermatitis; tested in 208 patients in a US and Korean Phase 2b trial, with the final study report received.
FROM PUBLIC EVENTS · 2026-11-18
Pipeline reshaping Has brought a beauty company into the group and is pursuing licensing deals based on clinical results for its atopic dermatitis and Alzheimer's candidates. Also seen: Early clinical · first deals
Roles often seen at this stageBD & licensing · Clinical & PV · Research & development
A Seoul-based KOSDAQ-listed developer of immunology drugs built on inflammasome-inhibitor and nanobody platforms, which also runs a beauty business after bringing NeedsTech into the group.
Topical candidate for mild-to-moderate atopic dermatitis; tested in 208 patients in a US and Korean Phase 2b trial, with the final study report received.
Oral Alzheimer's candidate acting on GPCR19; its Korean Phase 1 trial was completed in March 2026.
NeedsTech runs beauty brands including the hugrab beauty device line and the aubric inner-beauty line.
Received the final study report of the US and Korean Phase 2b trial of the atopic dermatitis candidate NuGel.
Discussed licensing and co-development of NuCerin with pharmaceutical companies at BioJapan 2026.
Recorded consolidated revenue of 4.8 billion won in Q3 2026 after bringing NeedsTech into the group.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.